$PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Healthcare
Sector
Biotechnology
Industry
Dinesh V. Patel
CEO
124
Employees
$122.63
Current Price
$5.19B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $1,061,460.00 | 9,000 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $2,030,580.00 | 18,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 8 | $16,355,220.00 | 161,130 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 9 | $16,539,792.50 | 162,880 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | Waddill William D. Director | Sale | 9,000 | $117.94 | $1,061,460.00 | View Details |
| Jun 10, 2026 | Waddill William D. Director | Sale | 9,000 | $107.68 | $969,120.00 | View Details |
| May 29, 2026 | Waddill William D. Director | Sale | 9,000 | $99.64 | $896,760.00 | View Details |
| May 12, 2026 | PATEL DINESH V PH D Director | Sale | 75,000 | $100.12 | $7,509,000.00 | View Details |
| May 7, 2026 | Giraudo Bryan Director | Sale | 36,000 | $100.14 | $3,605,040.00 | View Details |
| May 8, 2026 | Giraudo Bryan Director | Sale | 5,130 | $100.00 | $513,000.00 | View Details |
| May 8, 2026 | Giraudo Bryan Director | Sale | 6,000 | $100.00 | $600,000.00 | View Details |
| May 7, 2026 | Giraudo Bryan Director | Sale | 12,000 | $100.07 | $1,200,840.00 | View Details |
| Apr 20, 2026 | Ali Asif Chief Financial Officer | Sale | 1,750 | $105.47 | $184,572.50 | View Details |
28 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.